Icares Medicus Inc

Icares Medicus Inc has a market capitalization of TWD 3.25 billion and a price-to-earnings ratio of 63.35, indicating a high valuation relative to earnings. The company's price-to-book ratio is 1.77, suggesting that the market values the company at a premium to its book value. The liquidity position is mixed, with TWD 18.86 million in cash and equivalents but a negative net cash position after subtracting total debt. Profitability metrics show a return on equity of 2.79% and a return on assets of 1.61%, both below the industry median for medical equipment and supplies firms. The company's gross margin is 59.1%, calculated from a gross profit of TWD 668.18 million on revenue of TWD 1.13 billion, but operating margin is only 11.4%, reflecting high operating expenses. Net income is TWD 51.23 million, or TWD 1.08 per share, with a diluted EPS of the same amount. The company's revenue is derived from three main categories: royalty income from technology authorization, technical service income from surface treatment services and foundry operations, and sales of medical materials. The geographic exposure is primarily domestic, with limited details on overseas market distribution. No specific revenue concentration by segment or region is disclosed in the financial snapshot. Looking ahead, the company is projected to see a revenue growth of 5.2% in the current fiscal year and 3.8% in the next fiscal year. However, the operating cash flow is negative at TWD -58.83 million, and free cash flow is TWD 86.43 million, indicating a reliance on capital expenditures and operational efficiency to sustain growth. Capital expenditures for the period were TWD -53.47 million. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.48, and the current ratio is 2.04, suggesting a relatively stable short-term financial position. However, the negative net cash position after subtracting total debt is a key flag. No dilution sources are identified in the risk assessment, and the dilution potential is considered low. Recent events include the company's continued focus on high-end medical surface treatment technology and artificial lens development. No specific recent filings or transcripts are detailed in the input data, but the company's ongoing R&D efforts and market expansion are likely to be key drivers of future performance.